Chinese biopharmaceutical company: The inclusion of Lorlatinib tablets in the breakthrough therapy program.

Chinese Biopharmaceuticals announced that the Phase III clinical trial of Lofexidine for the treatment of moderate to severe cGVHD is currently in the subject recruitment stage. The group will accelerate the global clinical development of Lofexidine in order to bring better treatment options to patients worldwide as soon as possible.